en · de · es · fr · pt
analytical-notes.peptides6608.com › Guide › Cardarine As Investigational Pparδ Agonist — Questions and Answers

Cardarine As Investigational Pparδ Agonist — Questions and Answers

By Editorial Desk · published 2026-01-14 · last reviewed 2026-03-06 · Guide

fatty acid oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.

Cardarine as Investigational PPARδ Agonist

The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.

Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.

Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516, GW-501516, GW 501516, endurobolNames vary in research and anti-doping documents.
Chemical classSynthetic PPARδ agonistSmall-molecule nuclear receptor ligand.
CAS Registry Number317318-70-0Identifier commonly associated with GW501516.
AppearanceWhite to off-white powderTypical for purified research material.
SolubilityLow in water; soluble in DMSO and ethanolOrganic solvents are common for laboratory stock solutions.

Background and Research Context

Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.

PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.

In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.

Related pages on this site

Mechanism and Research Context

Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.

In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.

Background and Regulatory History

Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.

Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.

GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Notes from published material

Former Editor-in-Chief, Harvard Heart Letter Former guest editor, Journal of the American College of Cardiology Former chief medical editor, Cardiology Today's Intervention Deputy Editor, Clinical Cardiology. Deputy Editor, Progress in Cardiovascular Diseases

The society – which only admitted men at the time – initially mistook Benett for a man due to her reputation as a scientist and her unusual first name, addressing her diploma of admission to "Dominum" (Master) Benett. 1840: Scottish fossil collector and illustrator Lady Eliza Maria Gordon-Cumming invited geologists Louis Agassiz, William Buckland and Roderick Murchison to examine her collection of fish fossils. Agassiz confirmed several of Gordon-Cumming's discoveries as new species. 1843: During a nine-month period in 1842–43, English mathematician Ada Lovelace translated Luigi Menabrea's article on Charles Babbage's newest proposed machine, the Analytical Engine. With the article, she appended a set of notes. Her notes were labelled alphabetically from A to G. In note G, she describes an algorithm for the Analytical Engine to compute Bernoulli numbers. It is considered the first published algorithm ever specifically tailored for implementation on a computer, and Ada Lovelace has often been cited as the first computer programmer for this reason. The engine was never completed, so her program was never tested. 1843: British botanist and pioneering photographer Anna Atkins self-published her book Photographs of British Algae, illustrating the work with cyanotypes. Her book was the first book on any subject to be illustrated by photographs. 1846: British zoologist Anna Thynne built the first stable, self-sustaining marine aquarium.

Directed by Michael Bate and co-written by Bate and David McDonald, the production was inspired by a March 1973 interview that Bate conducted with Parsons, which became Parsons' last recorded conversation. In 2012, Swedish folk duo First Aid Kit released the single "Emmylou" from the album The Lion's Roar. The song's chorus is a lyrical acknowledgment of the Gram Parsons and Emmylou Harris singing partnership. In the fall of 2012 Florida festival promoter and musician Randy Judy presented his bio-musical Farther Along – The Music and Life of Gram Parsons at Magnoliafest at the Spirit of the Suwannee Music Park. Tribute bands include Cleveland's New Soft Shoe and, out of St. Paul, The Gilded Palace Sinners. In 2022, Dave Prinz, co-founder of Amoeba Music, rediscovered Gram Parsons' "Last Roundup" tapes featuring Emmylou Harris with Gram Parsons and the Fallen Angels. Prinz initiated a campaign to fund the release independently, in partnership with Polly Parsons. The campaign launched on November 17, 2022, and was fully backed. Gram Parsons & The Fallen Angels' "The Last Roundup: Live from The Bijou Café in Philadelphia 3/16/73" was released on limited-edition vinyl on Friday, November 24, 2023, and was considered one of the hits of Record Store Day 2023. In 2021, Zak Bagans and his crew on the hit TV show Ghost Adventures, with a special guest, investigated the Joshua Tree Inn to bring both closure and peace to the Parsons family. In 2026, a restaurant named "Grievous Angel" (named after the Gram Parsons album title) opened in Lakeland, Florida.

Sources: en.wikipedia.org

Further detail

== P == PAS – Positron annihilation spectroscopy Photoacoustic spectroscopy PAT or PACT – Photoacoustic tomography or photoacoustic computed tomography PAX – Photoemission of adsorbed xenon PC or PCS – Photocurrent spectroscopy Phase contrast microscopy PhD – Photoelectron diffraction PD – Photodesorption PDEIS – Potentiodynamic electrochemical impedance spectroscopy PDS – Photothermal deflection spectroscopy PED – Photoelectron diffraction PEELS – parallel electron energy loss spectroscopy PEEM – Photoemission electron microscopy (or photoelectron emission microscopy) PES – Photoelectron spectroscopy PINEM – photon-induced near-field electron microscopy PIGE – Particle (or proton) induced gamma-ray spectroscopy, see nuclear reaction analysis PIXE – Particle (or proton) induced X-ray spectroscopy PL – Photoluminescence Porosimetry Powder diffraction PTMS – Photothermal microspectroscopy PTS – Photothermal spectroscopy

Risperidone, sold under the brand name Risperdal among others, is an atypical antipsychotic used to treat schizophrenia and bipolar disorder, as well as aggressive and self-injurious behaviors associated with autism spectrum disorder. It is taken either by mouth or by injection (i.e., subcutaneous or intramuscular). The injectable versions are long-acting and last for 2–4 weeks. Common side effects include weight gain, drowsiness, fatigue, insomnia, dry mouth, constipation, elevated prolactin levels, and restlessness. Serious side effects may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, an increased risk of suicide, and high blood sugar levels. In older people with psychosis as a result of dementia, it may increase the risk of death. It is unknown if it is safe for use in pregnancy. Its mechanism of action is not entirely clear, but is believed to be related to its action as a dopamine and serotonin antagonist. Study of risperidone began in the late 1980s and it was approved for sale in the United States in 1993. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 176th most commonly prescribed medication in the United States, with more than 2 million prescriptions.

== Early life and education == Eke was born at the University of Nigeria Teaching Hospital in Enugu State, Nigeria. He attended Federal Government College, Wukari in Taraba State, before completing his medical degree (MBChB) at the University of Calabar. He earned a Master of Public Health (MPH) from the Harvard School of Public Health, concentrating in health policy and management. He completed residency training in Obstetrics and Gynecology in Nigeria at the Nnamdi Azikiwe University Teaching Hospital, and later at Michigan State University Obstetrics and Gynecology residency training program (now University of Michigan Health - Sparrow) in the United States. He went on to complete dual fellowships in maternal-fetal medicine and clinical pharmacology at Johns Hopkins University, where he earned a doctor of philosophy (PhD) in clinical investigation through the Graduate Training Program in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.

Sources: en.wikipedia.org

Supporting material

== Detecting peptides == Typically, peptide signals are detected at the MS1 level and distinguished from chemical noise through their characteristic isotopic pattern. These patterns are then tracked across the retention time dimension and used to reconstruct a chromatographic elution profile of the mono-isotopic peptide mass. The total ion current of the peptide signal is then integrated and used as a quantitative measurement of the original peptide concentration. For each detected peptide, all isotopic peaks are first found and the charge state is then assigned. Label-free quantification may be based on precursor signal intensity and has problems due to isolation interference: in high-throughput studies, the identity of the peptide precursor ion being measured could easily be a completely different peptide with a similar m/z ratio and which elutes in a time frame overlapping with that of the former peptide. Spectral counting has problems due to the fact that the peptides are identified, thus making it necessary to run an additional MS/MS scan which takes time and therefore reduces the resolution of the experiment.

== Politics == Manmohan Singh (1933–2024), former Prime Minister of India from 2004 to 2014 Ajit Pal Singh Kohli, Indian politician and MLA from Patiala Assembly constituency Amolak Rattan Kohli (born 1942), former governor of the Indian state of Mizoram from 2001 to 2006 Om Prakash Kohli (1935–2023), former governor of the Indian state of Gujarat from 2014 to 2019 Abdul Ghani Kohli (born 1943), Indian J&K politician Mohammad Aslam Kohli, Indian J&K politician Krishna Kohli (born 1979), Pakistani politician (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan) Kuli Kohli (born 1970), Indian-British poet, writer, disabled activist and local council member Veeru Kohli (1964–2023), Pakistani human rights activist (While her name is spelled as Kohli, she originates from the Koli people, who are unrelated to the Kohlis of the Khukhrain clan)

According to legend, one of the first blue cheeses, Roquefort, was discovered when a young boy, eating bread and ewes' milk cheese, abandoned his meal in a nearby cave after seeing a beautiful girl in the distance. When he returned months later, the mold (Penicillium roqueforti) had transformed his cheese into Roquefort. Gorgonzola is one of the oldest known blue cheeses, having been created around AD 879, though it is said that it did not contain blue veins until around the 11th century. Stilton is a relatively new addition, becoming popular sometime in the early 1700s. Many varieties of blue cheese originated subsequently, such as the 20th century Danablu and Cambozola, which were an attempt to fill the demand for Roquefort-style cheeses.

=== Selected publications === 2023, The Information Theory of Aging, Nature Aging 2023, Chemically induced reprogramming to reverse cellular aging, Aging 2023, Loss of epigenetic information as a cause of mammalian aging, Cell 2021, The economic value of targeting aging, Nature Aging 2020, Reprogramming to recover youthful epigenetic information and restore vision, Nature 2008, SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging, Cell

Sources: en.wikipedia.org

Frequently asked questions

What is cardarine?

Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.

Is cardarine a steroid?

No. Cardarine is not a steroid hormone; it targets the nuclear receptor PPARδ. Its classification in anti-doping rules differs from anabolic steroids, though it remains prohibited in sport.

Why was cardarine not developed further?

Early rodent studies reported tumor formation at multiple sites, which raised safety concerns. Sponsors stopped clinical development, and no approved human product exists.

How is cardarine detected in anti-doping tests?

Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.

Network